SG11202111671QA - Binding molecules - Google Patents

Binding molecules

Info

Publication number
SG11202111671QA
SG11202111671QA SG11202111671QA SG11202111671QA SG11202111671QA SG 11202111671Q A SG11202111671Q A SG 11202111671QA SG 11202111671Q A SG11202111671Q A SG 11202111671QA SG 11202111671Q A SG11202111671Q A SG 11202111671QA SG 11202111671Q A SG11202111671Q A SG 11202111671QA
Authority
SG
Singapore
Prior art keywords
binding molecules
molecules
binding
Prior art date
Application number
SG11202111671QA
Inventor
Grainne Dunlevy
Colette Johnston
Daniela Sydoruk
Martyna Lewandowska
Original Assignee
Crescendo Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906872.5A external-priority patent/GB201906872D0/en
Priority claimed from GBGB1906870.9A external-priority patent/GB201906870D0/en
Application filed by Crescendo Biologics Ltd filed Critical Crescendo Biologics Ltd
Publication of SG11202111671QA publication Critical patent/SG11202111671QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11202111671QA 2019-05-15 2020-05-15 Binding molecules SG11202111671QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1906872.5A GB201906872D0 (en) 2019-05-15 2019-05-15 Binding molecules
GBGB1906870.9A GB201906870D0 (en) 2019-05-15 2019-05-15 Binding molecules
PCT/GB2020/051199 WO2020229842A1 (en) 2019-05-15 2020-05-15 Binding molecules

Publications (1)

Publication Number Publication Date
SG11202111671QA true SG11202111671QA (en) 2021-11-29

Family

ID=70847430

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111671QA SG11202111671QA (en) 2019-05-15 2020-05-15 Binding molecules

Country Status (10)

Country Link
US (2) US20220220215A1 (en)
EP (2) EP3969474A1 (en)
JP (1) JP2022532370A (en)
KR (1) KR20220008839A (en)
CN (1) CN113840835B (en)
AU (1) AU2020275926A1 (en)
CA (1) CA3136598A1 (en)
IL (1) IL287555A (en)
SG (1) SG11202111671QA (en)
WO (2) WO2020229844A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7267921B2 (en) 2017-01-06 2023-05-02 クレシェンド・バイオロジックス・リミテッド Single domain antibody against programmed cell death (PD-1)
US20200362051A1 (en) 2017-11-13 2020-11-19 Crescendo Biologics Limited Molecules that bind to cd137 and psma
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
GB202205589D0 (en) 2022-04-14 2022-06-01 Crescendo Biologics Ltd Mesothelin binders
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
AU2007328900A1 (en) * 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
WO2012072731A2 (en) * 2010-12-01 2012-06-07 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
US9573992B2 (en) * 2011-06-23 2017-02-21 Ablynx N.V. Serum albumin binding proteins
WO2013167883A1 (en) * 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
WO2014111550A1 (en) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
EP3461848B1 (en) 2014-10-22 2023-10-11 Crescendo Biologics Limited Transgenic mice
WO2017201488A1 (en) * 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
AU2017373746A1 (en) * 2016-12-07 2019-05-30 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
CN107674122A (en) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 A kind of single domain antibody for identifying human serum albumins
JP7267921B2 (en) 2017-01-06 2023-05-02 クレシェンド・バイオロジックス・リミテッド Single domain antibody against programmed cell death (PD-1)
GB201711068D0 (en) * 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
US11155607B2 (en) * 2017-07-19 2021-10-26 Vib Vzw Serum albumin binding agents
EP3470426A1 (en) * 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
US20200362051A1 (en) * 2017-11-13 2020-11-19 Crescendo Biologics Limited Molecules that bind to cd137 and psma

Also Published As

Publication number Publication date
KR20220008839A (en) 2022-01-21
EP3969473A1 (en) 2022-03-23
AU2020275926A1 (en) 2021-11-18
US20220220215A1 (en) 2022-07-14
CN113840835A (en) 2021-12-24
JP2022532370A (en) 2022-07-14
WO2020229844A1 (en) 2020-11-19
CN113840835B (en) 2024-06-25
WO2020229842A1 (en) 2020-11-19
US20220227850A1 (en) 2022-07-21
CA3136598A1 (en) 2021-11-19
EP3969474A1 (en) 2022-03-23
IL287555A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
IL273631A (en) Hpv-specific binding molecules
IL281901A (en) Multivalent igm- and iga-fc-based binding molecules
IL289867A (en) Immunostimulatory multimeric binding molecules
GB201612520D0 (en) Binding molecules
GB201901306D0 (en) Multi-domain binding molecules
IL287555A (en) Binding molecules
GB201702091D0 (en) Specific binding molecules
GB201901305D0 (en) Specific binding molecules
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
GB201811410D0 (en) OX40 Binding molecules
IL289415A (en) Claudin-6 binding molecules and uses thereof
IL286013A (en) Cd3 binding molecules
IL289266A (en) Novel molecules
GB201811408D0 (en) CD137 Binding Molecules
GB201915282D0 (en) Specific binding molecules
IL288561A (en) Anti-gal9 immune-inhibiting binding molecules
EP3781204A4 (en) Binding molecules
IL269752B (en) Fgfr3 binding molecules
IL288562A (en) Activating anti-gal9 binding molecules
GB201803178D0 (en) Specific binding molecules for htert
GB201906118D0 (en) Anti-LAG-3 binding molecules
GB202010329D0 (en) Specific binding molecules
GB202006629D0 (en) Specific binding molecules
GB201912657D0 (en) Binding members
GB201914468D0 (en) Binding Molecules